A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis)

Mario Valenti,Luciano Ibba,Ruggero Cascio Ingurgio,Piergiorgio Malagoli,Andrea Carugno,Marco Campoli,Carlo G. Carrera,Francesca M. Gaiani,Davide Strippoli,Federica Mola,Angelo V. Marzano,Nicola Zerbinati,Anna Minuti,Antonio Costanzo,Alessandra Narcisi

DOI: https://doi.org/10.1007/s13555-024-01270-5

2024-10-15

Dermatology and Therapy

Abstract:Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis. However, long-term real-world data on its effectiveness in patients with inadequate response to ustekinumab are limited. This study investigates guselkumab's long-term effectiveness and safety in patients with psoriasis with partial response to ustekinumab.

dermatology